US 12,215,337 B2
Viral vectors and packaging cell lines
Andrew Scharenberg, Seattle, WA (US); and Laurie Beitz, Seattle, WA (US)
Assigned to Umoja Biopharma, Inc., Seattle, WA (US)
Appl. No. 17/046,701
Filed by Umoja Biopharma, Inc., Seattle, WA (US)
PCT Filed Apr. 11, 2019, PCT No. PCT/US2019/026923
§ 371(c)(1), (2) Date Oct. 9, 2020,
PCT Pub. No. WO2019/200056, PCT Pub. Date Oct. 17, 2019.
Claims priority of provisional application 62/656,823, filed on Apr. 12, 2018.
Prior Publication US 2021/0147871 A1, May 20, 2021
Int. Cl. C12N 15/86 (2006.01); A61K 9/00 (2006.01); A61K 31/436 (2006.01); A61K 38/13 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); C07K 14/55 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01)
CPC C12N 15/86 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 31/436 (2013.01); A61K 38/13 (2013.01); A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 38/1793 (2013.01); A61K 39/3955 (2013.01); C07K 14/55 (2013.01); C07K 14/70532 (2013.01); C07K 14/70578 (2013.01); C07K 16/2809 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/30 (2013.01); C12N 2740/15032 (2013.01); C12N 2740/15041 (2013.01); C12N 2740/15043 (2013.01); C12N 2740/15052 (2013.01); C12N 2740/16032 (2013.01); C12N 2740/16041 (2013.01); C12N 2740/16052 (2013.01)] 22 Claims
 
1. A lentiviral particle for activating and efficiently transducing T cells, comprising a nucleic acid sequence encoding a small molecule controllable T-cell/NK-cell activation receptor, the nucleic acid sequence operatively linked to a promoter, wherein the T-cell/NK-cell activation receptor is capable of being activated by the small molecule;
wherein the T-cell/NK-cell activation receptor comprises two polypeptide chains that comprise extracellular domains that bind the small molecule, and wherein the two polypeptide chains each comprise a transmembrane domain and an intracellular cytokine receptor signaling domain; and
wherein the lentiviral particle further comprises a viral surface comprising an anti-CD3 antibody or scFv.